Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSTAT vs ADDERALL 5
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextroamphetamine is a central nervous system stimulant that promotes release of dopamine and norepinephrine from presynaptic neurons, and inhibits their reuptake, thereby increasing synaptic concentrations of these neurotransmitters.
Adderall 5 is a combination of dextroamphetamine and amphetamine, which are central nervous system stimulants. They increase the levels of dopamine and norepinephrine in the synaptic cleft by inhibiting their reuptake and promoting their release from presynaptic neurons.
FDA-approved for attention deficit hyperactivity disorder (ADHD) and narcolepsy. Off-label uses include treatment-resistant depression, obesity, and cognitive enhancement in certain conditions.
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy
5-60 mg orally per day in divided doses, typically 5-10 mg 2-3 times daily, maximum 60 mg/day.
Initial: 5 mg orally once or twice daily; increase by 5 mg increments at weekly intervals. Maximum: 40 mg/day in divided doses.
Terminal elimination half-life is approximately 10-13 hours in adults, 6-8 hours in children. Extended duration allows once-daily dosing in some patients.
Immediate-release: 9–11 hours (mean 10 hours for dextroamphetamine); extended-release: 10–13 hours. Terminal half-life may be prolonged with urinary p H >7.
Primarily metabolized by hepatic CYP2D6 enzymes to inactive metabolites; also undergoes deamination and oxidation.
Amphetamine is metabolized via CYP2D6, with deamination and oxidation as major pathways.
Primarily renal (approximately 90% as unchanged drug and metabolites); minor biliary/fecal elimination (<10%).
Renal (90% as unchanged drug and metabolites; ~30% unchanged), minor fecal elimination (<5%).
15-40% bound to plasma proteins, primarily albumin.
~16% bound to plasma proteins (primarily albumin).
Approximately 3-4 L/kg, suggesting extensive tissue distribution.
3.5–4.5 L/kg; indicates extensive tissue distribution (e.g., brain, lungs).
Oral: approximately 60-70% due to first-pass metabolism; extended-release formulations have comparable bioavailability.
Oral immediate-release: 96–100% (first-pass metabolism minimal); extended-release: approximately 96% relative to immediate-release.
No specific guideline; use with caution and monitor for adverse effects in severe renal impairment (e GFR <30 m L/min/1.73m²).
GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: use maximum of 50% of usual dose; not recommended in ESRD.
No specific guideline; use with caution in severe hepatic impairment (Child-Pugh C) due to increased risk of toxicity.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
For ADHD: Children 6 years and older, start with 5 mg once or twice daily, increase by 5 mg weekly as tolerated; maximum 40 mg/day. Weight-based: 0.3-0.6 mg/kg/day.
Children 3-5 years: initial 2.5 mg daily, increase by 2.5 mg weekly; max 40 mg/day. Children ≥6 years: initial 5 mg once or twice daily, increase by 5 mg weekly; max 40 mg/day (or 20 mg/day for extended-release).
Start at lower doses, e.g., 2.5 mg once or twice daily, due to increased sensitivity and risk of side effects; monitor blood pressure and cardiac status.
Initiate at 2.5 mg once or twice daily; increase by 2.5-5 mg weekly; monitor for cardiovascular effects and confusion.
High potential for abuse and dependence. Prolonged use may lead to drug dependence. Misuse may cause sudden death or serious cardiovascular events.
Adderall has a high potential for abuse and dependence. Misuse may cause sudden death or serious cardiovascular events.
Serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities.,Blood pressure and heart rate increase; monitor for hypertension and tachycardia.,Psychiatric adverse events including exacerbation of pre-existing psychosis, mania, or aggression.,Seizures: may lower seizure threshold.,Peripheral vasculopathy including Raynaud's phenomenon.,Serotonin syndrome risk if used with serotonergic drugs.,Growth suppression in children; monitor growth during long-term use.
Serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities,Blood pressure and heart rate increases,Psychiatric adverse events such as psychosis or mania,Growth suppression in pediatric patients,Seizures,Peripheral vasculopathy including Raynaud's phenomenon,Serotonin syndrome when co-administered with serotonergic drugs
Hypersensitivity to amphetamines or any component of the formulation.,Concurrent use or within 14 days of monoamine oxidase inhibitors (MAOIs) due to hypertensive crisis.,Advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, glaucoma, agitated states, history of drug abuse.
Advanced arteriosclerosis,Symptomatic cardiovascular disease,Moderate to severe hypertension,Hyperthyroidism,Glaucoma,Agitated states,History of drug abuse,Concurrent use of MAOIs or within 14 days of discontinuing MAOI,Hypersensitivity to amphetamine products
Avoid acidic foods and juices (e.g., orange juice, grapefruit juice) within 1 hour of administration as they can reduce absorption. High-fat meals may delay absorption. Avoid alcohol and caffeine as they can exacerbate side effects.
Avoid acidic foods or vitamin C supplements within 1 hour of dosing as they decrease absorption. Grapefruit may increase drug levels. Caffeine and other stimulants should be limited. Avoid alcohol. High-fat meals may delay onset but not overall absorption.
First trimester: Limited data, but amphetamine use is associated with increased risk of premature delivery and low birth weight. Second and third trimesters: Risk of fetal growth restriction, increased neonatal heart rate, and neonatal withdrawal syndrome. Avoid use during pregnancy unless potential benefit justifies risk.
Pregnancy Category C (pre-2015) / Not assigned under current FDA labeling. First trimester: Studies suggest a possible small increased risk of congenital malformations, particularly cardiovascular defects and oral clefts, but absolute risk is low. Second and third trimesters: Exposure may increase risk of preterm delivery, low birth weight, and neonatal withdrawal symptoms including irritability, dysphoria, and feeding difficulties. Chronic use may lead to fetal growth restriction.
Amphetamines are excreted in human milk. M/P ratio not established. Breastfeeding not recommended due to potential adverse effects in infants including irritability, poor feeding, and growth suppression.
Amphetamine is excreted into human breast milk. The milk-to-plasma (M/P) ratio is approximately 2.0–3.0. Relative infant dose is estimated at 5–10% of the maternal weight-adjusted dose. Use while breastfeeding is generally not recommended due to potential adverse effects on the infant, including irritability, poor feeding, and insomnia. Consider alternative treatments or discontinue breastfeeding.
Pregnancy may increase clearance of amphetamines; dose adjustments may be necessary. Use the lowest effective dose. Clinical monitoring recommended.
Pharmacokinetic changes in pregnancy (increased volume of distribution, enhanced hepatic metabolism, and increased renal clearance) can lower amphetamine plasma concentrations. Dose adjustments may be necessary to maintain therapeutic effect; however, formal guidelines are lacking. Use the lowest effective dose and monitor clinical response. Avoid during pregnancy unless potential benefits outweigh risks.
Dextrostat (dextroamphetamine) is a central nervous system stimulant used for ADHD and narcolepsy. Monitor for hypertension, tachycardia, and psychiatric adverse effects. Avoid in patients with structural cardiac abnormalities, cardiomyopathy, or severe anxiety. Taper to discontinue to avoid withdrawal. Use with caution in patients with a history of substance abuse. May reduce seizure threshold.
ADDERALL 5 (amphetamine/dextroamphetamine) is a CNS stimulant. Note that 5 mg is a low starting dose; titrate based on response and tolerability. Avoid use in patients with structural cardiac abnormalities, glaucoma, hyperthyroidism, or history of drug abuse. Monitor for hypertension, tachycardia, and psychiatric symptoms. Can worsen tics or Tourette syndrome. Use with caution with MAOIs (risk of hypertensive crisis).
Take exactly as prescribed; do not increase dose without consulting your doctor.,Avoid taking late in the day to prevent insomnia.,Report any chest pain, shortness of breath, or fainting immediately.,Do not crush or chew extended-release capsules.,Avoid alcohol and over-the-counter cold remedies containing decongestants.,Store in a secure place; misuse can cause serious health problems.
Take exactly as prescribed; do not increase dose without consulting doctor.,Swallow tablet whole; do not crush or chew.,Avoid taking late in the day to prevent insomnia.,May cause dizziness; avoid driving if affected.,Report chest pain, shortness of breath, or fainting.,May be habit-forming; do not share with others.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSTAT vs ADDERALL 5, answered by our medical review team.
DEXTROSTAT is a CNS Stimulant that works by Dextroamphetamine is a central nervous system stimulant that promotes release of dopamine and norepinephrine from presynaptic neurons, and inhibits their reuptake, thereby increasing synaptic concentrations of these neurotransmitters.. ADDERALL 5 is a CNS Stimulant that works by Adderall 5 is a combination of dextroamphetamine and amphetamine, which are central nervous system stimulants. They increase the levels of dopamine and norepinephrine in the synaptic cleft by inhibiting their reuptake and promoting their release from presynaptic neurons.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSTAT and ADDERALL 5 depend on the specific clinical indication. These are both CNS Stimulant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSTAT is: 5-60 mg orally per day in divided doses, typically 5-10 mg 2-3 times daily, maximum 60 mg/day.. The standard adult dose of ADDERALL 5 is: Initial: 5 mg orally once or twice daily; increase by 5 mg increments at weekly intervals. Maximum: 40 mg/day in divided doses.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DEXTROSTAT and ADDERALL 5 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DEXTROSTAT is classified as Category C. First trimester: Limited data, but amphetamine use is associated with increased risk of premature delivery and low birth weight. Second and third trimesters: Risk of fetal growth r. ADDERALL 5 is classified as Category C. Pregnancy Category C (pre-2015) / Not assigned under current FDA labeling. First trimester: Studies suggest a possible small increased risk of congenital malformations, particularl. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.